Insights from 2023 ASH Annual Meeting | VuMedi

Insights from 2023 ASH Annual Meeting

Insights from 2023 ASH Annual Meeting

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

Insights from 2023 ASH Annual Meeting

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study

By Insights from 2023 ASH Annual Meeting FEATURING Paolo Ghia

By Insights from 2023 ASH Annual Meeting FEATURING Paolo Ghia

120 views

March 27, 2024

Genetic Advantages with Zanubrutinib in 1L CLL

00:00

Broad Efficacy of Zanubrutinib Across CLL Subgroups

02:34

Comments 0

Login to view comments. Click here to Login

Featured Video

Featured Video